Drug Type CAR-T |
Synonyms Anti-CD30/CD20 Dual CAR-T |
Target |
Mechanism CD20 modulators(B-lymphocyte antigen CD20 modulators), CD30 modulators(Tumor necrosis factor receptor superfamily member 8 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Triarm Therapeutics Ltd.Startup |
Active Organization Triarm Therapeutics Ltd.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hodgkin's Lymphoma | Preclinical | CN | Triarm Therapeutics Ltd.Startup | 21 Jun 2024 |
Non-Hodgkin Lymphoma | Preclinical | CN | Triarm Therapeutics Ltd.Startup | 21 Jun 2024 |